Gapping up
In reaction to strong earnings/guidance: BDE +15.2%, HCCI +14.4%, NES +7.1%, JMEI +6.7%,KVHI +6%, DSW +5.3%, SSH +4.4%, CDTI +4.1%, BURL +3.4%, LJPC +3.1%, QUNR +3.1%, CUI+1.6%, LEU +1%, ROSG +0.6%, .
M&A news: BHP +1.1% (recommended shareholders approve the proposed demerger of South32)
Select airline related names showing strength: JBLU +2.2%, LUV +2.1%, DAL +1.8%, SAVE+1.5%
Other news: BDE +15.2% (announced that it has engaged the financial advisory firms Rothschild Inc. and Robert W. Baird & Co. to lead the exploration of a full range of strategic alternatives for each of its brands; co also reported earnings), CNET +13.3% (has committed a cash investment for an ~10% ownership stake in O'Yummy Investment Management), IMNP +9.6% (to develop a novel topical nanoparticle formulation of AmiKet), FISI +7.3% (filed for $100 mln mixed securities shelf offering), AAL+5.6% (to replace AGN in the S&P 500), CLDX +5.3% (announces clinical trial collaboration with Roche to evaluate the combination of Varlilumab and MPDL3280A), AMRN +2.5% (announced the presentation of findings from a new in vitro study showing that pretreatment with eicosapentaenoic acid reduced oxidation of small dense LDL and resulted in improved endothelial function), MVIS +2.5% (cont strength), NXTD +1.6% (announced it has shipped Wocket smart wallets today), NUS +1.5% (received approval from China's Ministry of Commerce for the company to commence direct selling activities in Shaoxing City in Zhejiang Province), KIN +0.9% (announced positive results of pilot field study of KIND-012 for the control of fever in horses; Randomized, blinded, placebo-controlled Phase 2 study meets its primary endpoint)
Analyst comments: CNAT +4.1% (reinstated with a Buy at ROTH Capital), ATHM +0.9% (upgraded to Overweight from Equal Weight at Barclays), LXP +0.6% (upgraded to Buy from Neutral at Ladenburg Thalmann)
In reaction to strong earnings/guidance: BDE +15.2%, HCCI +14.4%, NES +7.1%, JMEI +6.7%,KVHI +6%, DSW +5.3%, SSH +4.4%, CDTI +4.1%, BURL +3.4%, LJPC +3.1%, QUNR +3.1%, CUI+1.6%, LEU +1%, ROSG +0.6%, .
M&A news: BHP +1.1% (recommended shareholders approve the proposed demerger of South32)
Select airline related names showing strength: JBLU +2.2%, LUV +2.1%, DAL +1.8%, SAVE+1.5%
Other news: BDE +15.2% (announced that it has engaged the financial advisory firms Rothschild Inc. and Robert W. Baird & Co. to lead the exploration of a full range of strategic alternatives for each of its brands; co also reported earnings), CNET +13.3% (has committed a cash investment for an ~10% ownership stake in O'Yummy Investment Management), IMNP +9.6% (to develop a novel topical nanoparticle formulation of AmiKet), FISI +7.3% (filed for $100 mln mixed securities shelf offering), AAL+5.6% (to replace AGN in the S&P 500), CLDX +5.3% (announces clinical trial collaboration with Roche to evaluate the combination of Varlilumab and MPDL3280A), AMRN +2.5% (announced the presentation of findings from a new in vitro study showing that pretreatment with eicosapentaenoic acid reduced oxidation of small dense LDL and resulted in improved endothelial function), MVIS +2.5% (cont strength), NXTD +1.6% (announced it has shipped Wocket smart wallets today), NUS +1.5% (received approval from China's Ministry of Commerce for the company to commence direct selling activities in Shaoxing City in Zhejiang Province), KIN +0.9% (announced positive results of pilot field study of KIND-012 for the control of fever in horses; Randomized, blinded, placebo-controlled Phase 2 study meets its primary endpoint)
Analyst comments: CNAT +4.1% (reinstated with a Buy at ROTH Capital), ATHM +0.9% (upgraded to Overweight from Equal Weight at Barclays), LXP +0.6% (upgraded to Buy from Neutral at Ladenburg Thalmann)